Safety, Efficacy, and Tolerability of Sofosbuvir and Ribavirin in Management of Recurrent Hepatitis C Virus Genotype 4 After Living Donor Liver Transplant in Egypt: What Have We Learned so far?

BACKGROUND: Recurrence of HCV after living donor liver transplant (LDLT) is nearly universal, with almost one third of recipients developing cirrhosis and graft failure within 5 years after LDLT. Different studies have been published on the effect of sofosbuvir after liver transplantation on recurre...

Descripción completa

Detalles Bibliográficos
Autores principales: Dabbous, Hany M., Montasser, Iman F., Sakr, Mohamed A., Refai, Rasha, Sayam, Moataz, Abdelmonem, Ahmed, Sayed, Hany, F. Abdelghafar, Mohamed, Bahaa, Mohamed, S. Elmeteini, Mahmoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2016
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912692/
https://www.ncbi.nlm.nih.gov/pubmed/27330537
http://dx.doi.org/10.5812/hepatmon.35339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912692/
https://www.ncbi.nlm.nih.gov/pubmed/27330537
http://dx.doi.org/10.5812/hepatmon.35339

Ejemplares similares